Contribution: Industrial Research Assistance Program – Contributions to Firms
JN NOVA PHARMA INC
$4,609,000.00
COVID-19 Response: Development of novel COVID-19 Therapeutics utilizing Precision Medicine approach
FY 2020-21 · 2020-10-05
Summary
Development of a proprietary biological drug to block Coronavirus infectivity, whilst reducing induced pathology in symptomatic patients, permitting a faster recovery and avoiding multiple organ injuries
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Montreal|Montreal, Quebec, Canada
Recipient Type
For-profit organization
Business Number
726018930
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2020-10-05 | 2020-21 | $4,609,000.00 |
| 3 | 2020-10-05 | 2020-21 | $4,609,000.00 |
| 4 | 2020-10-05 | 2020-21 | $4,609,000.00 |
| 5 | 2020-10-05 | 2020-21 | $4,609,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 59 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 59 jours.
Agreement End Date
2023-03-31
Agreement Number
960289
Agreement Start Date
2020-10-05
Agreement Title
COVID-19 Response: Development of novel COVID-19 Therapeutics utilizing Precision Medicine approach
Agreement Title (French)
Réponse face à la COVID-19 : Développement de nouvelles thérapies contre la COVID-19 en utilisant l'approche de la médecine de précision
Agreement Type
Contribution
Agreement Value
$4,609,000.00
Amendment Date
2023-01-03
Amendment Number
5
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Development of a proprietary biological drug to block Coronavirus infectivity, whilst reducing induced pathology in symptomatic patients, permitting a faster recovery and avoiding multiple organ injuries
Description (French)
Développement d'un médicament biologique breveté pour bloquer l'infectivité du coronavirus, tout en réduisant la pathologie induite chez les patients symptomatiques, permettant une récupération plus rapide et évitant les lésions multiples des organes.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding (French)
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding Number
24077
NAICS Code
3254
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
726018930
Recipient City
Montreal|Montreal
Recipient Country
CA
Recipient Legal Name
JN NOVA PHARMA INC
Recipient Postal Code
H3B 4W5
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2020-2021-Q3-960289
